Caribou Biosciences Shares Are Trading Lower After the Company Presented Clinical Data From the CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 ASCO Annual Meeting.
Caribou Biosciences Shares Are Trading Lower After the Company Presented Clinical Data From the CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 ASCO Annual Meeting.
Caribou Biosciences股票下跌，原因是該公司在2024年ASCO年會上公佈CB-010 ANTLER一期試驗在二線LBCL患者中的臨牀數據。
Caribou Biosciences Shares Are Trading Lower After the Company Presented Clinical Data From the CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 ASCO Annual Meeting.
Caribou Biosciences股票下跌，因公司在2024年ASCO年會上發佈了CB-010 ANTLER相1期試驗中第二線LBCL患者的臨床數據。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。